复星医药跨国并购Gland Pharma效应与风险分析  

作　　者：吴兰 黎芊含 

机构地区：[1]上海海关学院,上海浦东201204

出　　处：《产业创新研究》2018年第10期23-25,共3页Industrial Innovation

基　　金：2018年上海海关学院重点课程<跨国公司管理>(3202055A18)阶段性成果

摘　　要：21世纪以来,我国医药市场也成为仅次于美国的全球第二大医药市场,我国部分医药企业也逐步进行全球布局和经营。2017年,上海复星医药(集团)股份有限公司耗资10.91亿美元收购印度Gland Pharma公司,虽能获得拓展海外市场、战略互补、合作市场前景巨大等优势,但也存在中印关系不稳定、印度外资政策变动、组织架构调整、人员整合、文化协同等挑战。Since 21^st century, China＇s position in the global economy has been gradually improved, and China＇s pharmaceutical market has become the second largest in the world after that of the United States. Some Chinese pharmaceutical enterprises have gradually stepped into the international market and started to make global layout and operation. In 2017, Shanghai fosun pharmaceutical （group） co., LTD., a $1.091 billion acquisition of Indian Gland Pharma company, can expand overseas market, the advantages of the strategic complementary, huge market prospects for cooperation, but also exist in china-india relations is not stable, Indian foreign policy change, organization structure adjustment, integration and cultural synergy personnel challenges.

关 键 词：跨国并购 复星医药 GLAND Pharma 效应 风险 

分 类 号：F426.72[经济管理—产业经济] F271